CR20250175A - Agonistas de ahr - Google Patents
Agonistas de ahrInfo
- Publication number
- CR20250175A CR20250175A CR20250175A CR20250175A CR20250175A CR 20250175 A CR20250175 A CR 20250175A CR 20250175 A CR20250175 A CR 20250175A CR 20250175 A CR20250175 A CR 20250175A CR 20250175 A CR20250175 A CR 20250175A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- ahr agonists
- ahr
- psoriasis
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263425442P | 2022-11-15 | 2022-11-15 | |
| PCT/US2023/078633 WO2024107555A1 (en) | 2022-11-15 | 2023-11-03 | Ahr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250175A true CR20250175A (es) | 2025-05-27 |
Family
ID=89121650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250175A CR20250175A (es) | 2022-11-15 | 2023-11-03 | Agonistas de ahr |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240199608A1 (https=) |
| EP (1) | EP4619401A1 (https=) |
| JP (2) | JP7577819B2 (https=) |
| KR (1) | KR20250083557A (https=) |
| CN (1) | CN120225518A (https=) |
| AR (1) | AR131070A1 (https=) |
| AU (1) | AU2023382389A1 (https=) |
| CL (1) | CL2025001421A1 (https=) |
| CO (1) | CO2025005456A2 (https=) |
| CR (1) | CR20250175A (https=) |
| DO (1) | DOP2025000111A (https=) |
| IL (1) | IL320832A (https=) |
| JO (1) | JOP20250109A1 (https=) |
| MX (1) | MX2025005566A (https=) |
| PE (1) | PE20251588A1 (https=) |
| TW (2) | TW202523664A (https=) |
| WO (1) | WO2024107555A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240124A1 (en) * | 2024-05-14 | 2025-11-20 | Eli Lilly And Company | Processes for preparing enantiomeric compounds and related molecules |
| CN120904199B (zh) * | 2025-09-30 | 2026-03-06 | 上海泽德曼医药科技有限公司 | 具有稠环结构的化合物及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2510528A1 (de) * | 1975-03-11 | 1976-09-23 | Hoechst Ag | Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung |
| NL7709746A (nl) * | 1976-09-09 | 1978-03-13 | Hoechst Ag | Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen. |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| CN1149214C (zh) * | 1998-12-04 | 2004-05-12 | 东丽株式会社 | 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂 |
| DK1527050T3 (da) * | 2002-07-25 | 2010-07-19 | Janssen Pharmaceutica Nv | Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer |
| EP1613625A1 (en) * | 2003-03-14 | 2006-01-11 | AstraZeneca AB | Novel fused triazolones and the uses thereof |
| JP2007506788A (ja) * | 2003-09-26 | 2007-03-22 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｈｃｖ感染阻害剤とその使用法 |
| AU2005249231B2 (en) * | 2004-05-28 | 2010-11-11 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| WO2007074491A1 (en) * | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
| WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| WO2018171602A1 (zh) * | 2017-03-21 | 2018-09-27 | 正大天晴药业集团股份有限公司 | 用于ido和tdo双重抑制剂的脲类化合物 |
| WO2020231739A2 (en) * | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
| AR126963A1 (es) * | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
-
2023
- 2023-11-03 US US18/501,175 patent/US20240199608A1/en active Pending
- 2023-11-03 WO PCT/US2023/078633 patent/WO2024107555A1/en not_active Ceased
- 2023-11-03 EP EP23818599.5A patent/EP4619401A1/en active Pending
- 2023-11-03 IL IL320832A patent/IL320832A/en unknown
- 2023-11-03 PE PE2025000850A patent/PE20251588A1/es unknown
- 2023-11-03 AU AU2023382389A patent/AU2023382389A1/en active Pending
- 2023-11-03 KR KR1020257015398A patent/KR20250083557A/ko active Pending
- 2023-11-03 CN CN202380078645.4A patent/CN120225518A/zh active Pending
- 2023-11-03 CR CR20250175A patent/CR20250175A/es unknown
- 2023-11-15 AR ARP230103075A patent/AR131070A1/es unknown
- 2023-11-15 TW TW114105013A patent/TW202523664A/zh unknown
- 2023-11-15 TW TW112144125A patent/TWI870104B/zh active
- 2023-11-15 JP JP2023194117A patent/JP7577819B2/ja active Active
-
2024
- 2024-10-23 JP JP2024186560A patent/JP2025032072A/ja active Pending
-
2025
- 2025-04-29 CO CONC2025/0005456A patent/CO2025005456A2/es unknown
- 2025-05-13 CL CL2025001421A patent/CL2025001421A1/es unknown
- 2025-05-13 JO JOJO/P/2025/0109A patent/JOP20250109A1/ar unknown
- 2025-05-13 MX MX2025005566A patent/MX2025005566A/es unknown
- 2025-05-14 DO DO2025000111A patent/DOP2025000111A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20251588A1 (es) | 2025-06-16 |
| IL320832A (en) | 2025-07-01 |
| JOP20250109A1 (ar) | 2025-05-13 |
| CL2025001421A1 (es) | 2025-08-18 |
| TW202434583A (zh) | 2024-09-01 |
| JP2025032072A (ja) | 2025-03-11 |
| EP4619401A1 (en) | 2025-09-24 |
| WO2024107555A1 (en) | 2024-05-23 |
| AR131070A1 (es) | 2025-02-12 |
| JP2024072283A (ja) | 2024-05-27 |
| JP7577819B2 (ja) | 2024-11-05 |
| US20240199608A1 (en) | 2024-06-20 |
| KR20250083557A (ko) | 2025-06-10 |
| DOP2025000111A (es) | 2025-06-15 |
| MX2025005566A (es) | 2025-06-02 |
| TWI870104B (zh) | 2025-01-11 |
| AU2023382389A1 (en) | 2025-05-15 |
| TW202523664A (zh) | 2025-06-16 |
| CN120225518A (zh) | 2025-06-27 |
| CO2025005456A2 (es) | 2025-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2025000111A (es) | Agonistas de ahr | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| MX2021000142A (es) | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. | |
| CL2024001313A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| CO2024011455A2 (es) | Moduladores de il-17a basados en diciclopropilo y usos de estos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| MX2024003107A (es) | Agonistas de ahr. | |
| MX2023013001A (es) | Compuestos para inhibir o degradar itk, composiciones que comprenden los mismos, metodos para su elaboracion y metodos para su uso. | |
| MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| CO2023008475A2 (es) | Inhibidores de enzimas | |
| CL2023002274A1 (es) | Compuestos tricíclicos y usos de los mismos | |
| MX2025004910A (es) | Agonistas de ahr | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| BR112023014818A2 (pt) | Uso de ésteres de cetona exógena para induzir perda de peso em mamíferos | |
| MX2025008172A (es) | Composiciones a base de extracto de epilobium fleischeri para el tratamiento de los signos del envejecimiento | |
| MX2025014381A (es) | Inhibidores de tyk2 | |
| ECSP24007534A (es) | Inhibidores de transglutaminasas | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| CL2023002064A1 (es) | Derivados de ácido urólico sintético y métodos de uso de estos | |
| MX2024003111A (es) | Agonistas de ahr. | |
| AR134655A1 (es) | Péptidos cíclicos conjugados con ácidos grasos | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades |